These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22395694)

  • 1. HIV-1 Env antibodies: are we in a bind or going blind?
    Moore JP
    Nat Med; 2012 Mar; 18(3):346-7; author reply 347-8. PubMed ID: 22395694
    [No Abstract]   [Full Text] [Related]  

  • 2. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question.
    Hope TJ
    Nat Med; 2011 Oct; 17(10):1195-7. PubMed ID: 21988997
    [No Abstract]   [Full Text] [Related]  

  • 3. HIV neutralizing antibodies reignite interest in vaccine.
    Waltz E
    Nat Biotechnol; 2012 Mar; 30(3):204-5. PubMed ID: 22398603
    [No Abstract]   [Full Text] [Related]  

  • 4. Live rubella vectors can express native HIV envelope glycoproteins targeted by broadly neutralizing antibodies and prime the immune response to an envelope protein boost.
    Virnik K; Nesti E; Dail C; Scanlan A; Medvedev A; Vassell R; McGuire AT; Stamatatos L; Berkower I
    Vaccine; 2018 Aug; 36(34):5166-5172. PubMed ID: 30037665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 6. New center focuses on neutralizing antibodies.
    McEnery R
    IAVI Rep; 2008; 12(5):15. PubMed ID: 20210066
    [No Abstract]   [Full Text] [Related]  

  • 7. Broadly Neutralizing Antibodies and the Development of Vaccines.
    Haynes BF; Bradley T
    JAMA; 2015 Jun 23-30; 313(24):2419-20. PubMed ID: 26103022
    [No Abstract]   [Full Text] [Related]  

  • 8. HIV surface proteins finally caught going au naturel.
    Cohen J
    Science; 2013 Nov; 342(6158):546-7. PubMed ID: 24179198
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.
    Phillips B; Fouda GG; Eudailey J; Pollara J; Curtis AD; Kunz E; Dennis M; Shen X; Bay C; Hudgens M; Pickup D; Alam SM; Ardeshir A; Kozlowski PA; Van Rompay KKA; Ferrari G; Moody MA; Permar S; De Paris K
    Clin Vaccine Immunol; 2017 Oct; 24(10):. PubMed ID: 28814388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RV144: old vs. new.
    Weiner DB
    Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335
    [No Abstract]   [Full Text] [Related]  

  • 11. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
    Gonzalez-Figueroa P; Roco JA; Vinuesa CG
    Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly neutralizing antibodies and vaccine design against HIV-1 infection.
    Wang Q; Zhang L
    Front Med; 2020 Feb; 14(1):30-42. PubMed ID: 31858368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies: beyond neutralization.
    von Bubnoff A
    IAVI Rep; 2010; 14(1):8-12. PubMed ID: 20349583
    [No Abstract]   [Full Text] [Related]  

  • 15. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV vaccine development--improving on natural immunity.
    Johnston MI; Fauci AS
    N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447
    [No Abstract]   [Full Text] [Related]  

  • 17. New mouse models provide insights into how to design a more effective HIV vaccine.
    Harper KN
    AIDS; 2017 Jan; 31(3):N3-N4. PubMed ID: 28002067
    [No Abstract]   [Full Text] [Related]  

  • 18. HIV vaccine design: the neutralizing antibody conundrum.
    Stamatatos L
    Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693
    [No Abstract]   [Full Text] [Related]  

  • 19. HIV Vaccines: One Step Closer.
    Low MSY; Tarlinton D
    Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
    Landais E; Moore PL
    Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.